McGuireWoods partner Allyson Maur shared insights with Law360 in a Feb. 17, 2026, article examining the U.S. Food & Drug Administration’s enforcement campaign targeting pharmaceutical advertising.
The article focuses on the FDA’s recent enforcement letter to Novo Nordisk regarding a TV commercial for the company’s Wegovy weight loss pill. The letter underscores the FDA’s increased scrutiny of on-screen images, comparisons to other products and promotional claims promising improved quality of life, Law360 reported.
Maur, a healthcare partner whose clients include biopharmaceutical companies, warned that the FDA’s enforcement action signals more to come.
“Everybody should be prepared. I think this may just be the beginning,” Maur told Law360.
Maur said pharmaceutical companies should take a holistic view of their promotional materials, looking beyond individual words or images. Regulators are flagging ads they believe overpromise lifestyle changes, she explained.
“They’re looking at everything from the music to the words,” she said.